A study looking at intranasal insulin in mild cognitive impairment (MCI) and early AD found that the apolipoprotein (apo)E genotype affected the results such that benefits were greater in those not carrying the apoE4 allele, a known risk factor for AD [110]. This evidence concerns the gene APOE and Cognitive impairment.